Evaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan

Launched by FRESENIUS KABI TAIWAN LTD. · Mar 23, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients receiving chemotherapy and/or radiotherapy, or immunotherapy, or targeted therapy;
• • 2. Patient with diagnosed cancer of any type (e.g., head and neck cancer, lung cancer, digestive tract cancer, breast cancer);
• • 3. Patient with or at risk of malnutrition defined as meeting Malnutrition Universal Screening Tool (MUST) with score ≥2;
• • 4. Capable of using oral nutritional supplementation;
• • 5. Written informed consent from patient.
• Exclusion Criteria:
• • 1. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study;
• • 2. Current alcohol or substance abuse as assessed by Investigator;
• • 3. Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening;
• • 4. Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study;
• • 5. Pregnant or breastfeeding woman;
• • 6. Allergic to any ingredient of the investigational products;
• • 7. Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days;
• • 8. Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days;
• • 9. Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening;
• • 10. Transfusion of blood products within 1 week before screening;
• • 11. Surgery scheduled during the trial;
• • 12. Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.